Depending on the presence of a BRAF mutation, BRAF inhibitors can be employed in about 50% of patients with metastatic melanoma. The most significant effect is an increase in the disease-free interval from 1.6 to 5.5 months and an improvement in the 12-month survival rate from 43% to 55%.
BRAF inhibitors are oral drugs that have relatively mild side-effects.